6 September 2018 a definitive agreement with Sandoz, USA to acquire its dermatology and oral solids businesses. The upfront purchase price is USD900m in cash, which includes a potential upside in near-term earn-out and additional potential earn-out on pipeline products in outer years. The portfolio to be acquired has a revenue contribution of 70% from oral solids and 30% from dermatology. ARBP guided for sales of USD900m in the first 12 months after the closure of transaction, adjusting for the expiration of certain in-licensed product contracts and the rationalization of the acquired products. acquisition will add ~300 products, including those that are already commercialized and also the ones that are yet to be approved. The deal also adds two derma- dedicated manufacturing facilities (including dermatology dedicated R&D; facility) in the US. The sales guidance of USD900m on a 12-month basis post the closure of transaction and the EBITDA margin guidance of ~22-23% imply an EBITDA of ~USD198m.